EUNew treatments and approvals
Conditional EU approval for belzutifan for tumors linked to von Hippel-Lindau disease
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The EU granted conditional approval to belzutifan, which is taken by mouth. The approval covers adults with kidney, brain and pancreatic tumors. In these patients, local procedures such as surgery must not be suitable. In the main trial, tumors shrank or disappeared in 41 of 61 patients with kidney tumors. The trial had no comparison group.
What does it mean for patients and families?
Conditional approval means that more data are expected. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with your doctor.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Von Hippel-Lindau disease (VHL)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.